[Shanghai Yizhong: ASCO Annual meeting presents Clinical data of Paclitaxel Polymer micelles for injection combined with first-line Immunization in the treatment of Advanced squamous non-small Cell Lung Cancer] Shanghai Friends announced that the clinical practice data of the company's core product paclitaxel polymer micelles for injection combined with PD-1 and carboplatin in the treatment of advanced squamous non-small cell lung cancer (NSCLC) was selected into the 2023 American Society of Clinical Oncology (ASCO) annual meeting. The clinical data were a retrospective study of the real-world clinical practice of paclitaxel micelles combined with immunodrugs in the treatment of advanced squamous NSCLC. A total of 45 patients were treated with the regimen, with a median age of 68 years (41-84), 3 of whom had baseline brain metastasis. The summary of the research data was recently disclosed on the website of the 2023ASCO annual meeting. The data showed that of the 45 patients treated, 2 achieved complete remission (CR), 36 achieved partial remission (PR), 7 achieved disease stability (SD), the overall objective remission rate (ORR) was 84.4%, and the disease control rate (DCR) was 100%.